Roche GR41987 RHONE-X
Posted by: Georgia Retina in
Research Title: A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X) Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI)…
Read More
SamChungDang SCD411-CP101
Posted by: Georgia Retina in
Research Title: A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea® in Subjects With Neovascular Age-related Macular Degeneration Sponsor: Sam Chung Dang Pharm. Co. Ltd. Principal Investigator: Robert A. Stoltz, MD, PhD Description: Age-related macular degeneration (AMD) is a leading cause of vision loss in adults….
Read More Xbrane XBR1002 XPLORE
Posted by: Georgia Retina in
Research Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration (XPLORE). Sponsor: Xbrane BioPharma AB Principal Investigator: Atul Sharma, M.D. Description: The objectives of this study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (i.e.,…
Read More Roche GR40844 LUCERNE
Posted by: Georgia Retina in
Research Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (LUCERNE) Sponsor: Genentech, Inc. / Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in…
Read More Roche GR41675 PAVILION
Posted by: Georgia Retina in
Research Title: A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the…
Read More Roche GR40549 PORTAL
Posted by: Georgia Retina in
Research Title: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) 100 mg/mL with…
Read More Roche GR40550 PAGODA
Posted by: Georgia Retina in
Research Title: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients with Diabetic Macular Edema (Pagoda) Sponsor: Hoffmann-La Roche Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in…
Read More Regeneron VGFTe(HD)-DME-1934 PHOTON
Posted by: Georgia Retina in
Research Title: Sponsor: Principal Investigator: Description: Start Date: Recruitment: Project Personnel: Location(s):
Read More Novartis CRTH258B2305 Kingfisher
Posted by: Georgia Retina in
Research Title: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER) Sponsor: Novartis Pharmaceuticals Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: In this 12-month, randomized, double-masked,multicenter, active controlled study, consenting patients will be randomized in a 2:1 ratio (brolucizumab:…
Read More Novo Nordisk NN9535-4352 FOCUS
Posted by: Georgia Retina in
Research Title: Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes Sponsor: Novo Nordisk A/S Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2…
Read More 
